Intrinsic genetic instability of normal human lymphocytes and its implication for loss of heterozygosity. 2001

A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
MGC-Department of Radiation Genetics and Chemical Mutagenesis, Leiden University Medical Center, Leiden, The Netherlands.

A combination of flow cytometry and microsatellite analysis was used to investigate loss of expression of HLA-A and/or HLA-B alleles and concurrent LOH at polymorphic chromosome 6 loci both in freshly isolated lymphocytes (in vivo mutations) and in lymphocytes cultured ex vivo. The fraction of in vivo mutants that showed LOH at 6p appeared to vary from 0%-49% for various donors. During culturing ex vivo, HLA-A(-) cells arose at a high rate and showed simultaneous loss of expression at the linked HLA-B locus. Up to 90% of the ex vivo arisen HLA-A2(-) cell population showed LOH of multiple 6p markers, and 50% had lost heterozygosity at 6q. This ex vivo spectrum resembles that found in HLA-A2 mutants obtained from lymphoblastoid cells. The HLA-A2 mutants present in vivo may reflect only a small fraction of the mutants that can be detected ex vivo. In normal lymphocytes, in vivo only mitotic recombination appears to be sustained, indicating the importance of this mechanism for tumor initiation in normal cells. Although mutations resulting in LOH at both chromosome 6 arms were shown to result in nonviable cells in normal lymphocytes, they have been shown to result in viable mutants in lymphoblastoid cells. We hypothesize that these types of mutations also occur in vivo but only survive in cells that already harbor a mutated genetic background. In light of the high rate at which these types of mutations occur, they may contribute to cancer progression.

UI MeSH Term Description Entries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015789 HLA-A2 Antigen A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family. HLA Class I Histocompatibility Antigen, A-2 alpha Chain,HLA-A2,Antigen, HLA-A2,HLA A2 Antigen,HLA Class I Histocompatibility Antigen, A 2 alpha Chain
D015791 HLA-A3 Antigen A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*03 allele family. HLA Class I Histocompatibility Antigen, A-3 alpha Chain,HLA-A3,Antigen, HLA-A3,HLA A3 Antigen
D017384 Sequence Deletion Deletion of sequences of nucleic acids from the genetic material of an individual. Deletion Mutation,Deletion Mutations,Deletion, Sequence,Deletions, Sequence,Mutation, Deletion,Mutations, Deletion,Sequence Deletions
D018655 Lymphocyte Count The number of LYMPHOCYTES per unit volume of BLOOD. Total Lymphocyte Count,Lymphocyte Number,Lymphocyte Count, Total,Lymphocyte Counts,Lymphocyte Counts, Total,Lymphocyte Numbers,Total Lymphocyte Counts

Related Publications

A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
June 1997, The British journal of ophthalmology,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
August 1996, Biochemical and biophysical research communications,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
January 2009, Folia histochemica et cytobiologica,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
December 2003, Revista medica de Chile,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
May 1998, Mutation research,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
May 2006, British journal of cancer,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
January 1997, British journal of cancer,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
March 1998, Genes, chromosomes & cancer,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
August 1999, Liver,
A G de Nooij-Van Dalen, and B Morolli, and M van der Keur, and A van der Marel, and P H Lohman, and M Giphart-Gassler
October 1995, The Journal of investigative dermatology,
Copied contents to your clipboard!